| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 3.273 | 1.102 | 2.128 | 4.077 | 2.434 | 1.613 | 1.213 | 0 | 36.692 | 37.969 |
| Total Income - EUR | 3.273 | 1.102 | 2.128 | 4.077 | 2.434 | 1.613 | 1.617 | 334 | 36.693 | 37.975 |
| Total Expenses - EUR | 2.415 | 2.048 | 1.130 | 2.062 | 1.668 | 587 | 1.196 | 315 | 16.239 | 24.543 |
| Gross Profit/Loss - EUR | 858 | -945 | 998 | 2.015 | 766 | 1.026 | 421 | 19 | 20.454 | 13.431 |
| Net Profit/Loss - EUR | 760 | -978 | 933 | 1.895 | 692 | 981 | 379 | 16 | 20.128 | 10.967 |
| Employees | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
Check the financial reports for the company - Epibionic S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 18 | 1.248 | 1.056 | 0 | 0 | 0 | 1.388 |
| Current Assets | 2.729 | 1.691 | 2.932 | 1.913 | 1.855 | 3.062 | 3.907 | 216 | 21.809 | 13.094 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 270 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 13.809 | 5.430 |
| Cash | 2.459 | 1.691 | 2.932 | 1.913 | 1.855 | 3.062 | 3.907 | 216 | 8.000 | 7.664 |
| Shareholders Funds | 2.471 | 1.468 | 2.376 | 1.971 | 2.625 | 3.557 | 3.856 | 88 | 20.216 | 11.039 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 258 | 223 | 556 | 30 | 581 | 561 | 153 | 128 | 2.420 | 3.718 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Epibionic S.r.l.